Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences
Cancers · 15.07.2026 · 18 (14) · 2265
DOI: 10.3390/cancers18142265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 15.07.2026. Verfasst von Minji K Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, CCR NIH HHS.
Abstract (Originalsprache)
Background/Objectives: The PRO-CTCAE Average Composite Score (ACS), calculated as the mean of PRO-CTCAE composite scores, summarizes overall symptom and side effect burden. This study evaluated the test–retest reliability, responsiveness to change, known-groups validity, and sensitivity to group differences in the ACS.
Methods
Analyses used the original PRO-CTCAE validation dataset, including lung (n = 174), breast (n = 222), and head and neck (n = 139) cancer cohorts, and data from the COMET-2 randomized phase III trial comparing cabozantinib (n = 53) and mitoxantrone–prednisone (n = 54) in men with previously treated prostate cancer. Test–retest reliability was assessed using intraclass correlation coefficients (ICCs) from two-way mixed-effects models for agreement. Responsiveness was evaluated by relating ACS change scores (Visit 1 minus follow-up Visit 2) to patient-reported global ratings of change (GRC; worsened, unchanged, or improved) using standardized response means (SRMs) and Jonckheere–Terpstra trend tests. Known-groups validity was examined by comparing mean ACS values between ECOG performance status groups (0–1 vs. 2–4). Sensitivity to treatment group differences was assessed using model-based area-under-the-curve (AUC) comparisons of longitudinal ACS trajectories.
Results
Test–retest reliability was acceptable, with ICCs among GRC-defined stable patients of 0.80 (95% CI: 0.70–0.87) in lung cancer, 0.84 (95% CI: 0.77–0.89) in breast cancer, and 0.77 (95% CI: 0.63–0.86) in head and neck cancer; ICCs based on assessments completed one day apart ranged from 0.88 to 0.90. The ACS demonstrated responsiveness, with SRMs of 0.30/0.15/−0.37 (lung), 0.29/0.14/−0.40 (breast), and −0.01/−0.20/−0.56 (head/neck) for improved/no-change/worsened groups, respectively, and significant monotonic trends across GRC categories (all p < 0.01). Known-groups validity was supported by conceptually expected differences in ACS values across distinct levels of self-reported patient-reported physical functioning and ECOG performance status categories. Mean ACS values were lower among patients with good versus limited physical functioning (0.71 vs. 1.23 in lung cancer, 0.52 vs. 1.19 in breast cancer, and 0.69 vs. 1.29 in head and neck cancer) and among patients with ECOG PS 0–1 versus 2–4 (0.93 vs. 1.31, 0.74 vs. 1.22, and 0.90 vs. 1.06, respectively). In COMET-2, higher symptom burden was detected in the cabozantinib arm compared with the mitoxantrone–prednisone arm (AUC difference = 1.5, 95% CI: 0.2–2.8, p = 0.02).
Conclusions
The ACS demonstrated acceptable test–retest reliability, responsiveness, and known-groups validity across multiple cancer populations. These findings support its use as a complementary summary measure of overall symptomatic adverse event burden alongside individual symptom-level analyses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ 85259, USA.
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
- Center for Cancer Research, National Cancer Institute, Rockville, MD 20850, USA.
- Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD 20850, USA.
ORCID-Profile: Minji K Lee, Amylou C Dueck, Gina L Mazza, Allison M Deal, Lauren Rogak, Sandra A Mitchell
Förderung
- NIH HHS
- NCI NIH HHS
- CCR NIH HHS
- US National Cancer Institute
- Exelixis, Inc.
Zitieren
APA
Lee, M. K., Dueck, A. C., Langlais, B. T., Mazza, G. L., Thanarajasingam, G., Deal, A. M., Noble, B. N., Rogak, L., Mendoza, T. R., Mitchell, S. A., & Basch, E. (2026). Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences. Cancers, 18(14), 2265. https://doi.org/10.3390/cancers18142265
Vancouver
Lee MK, Dueck AC, Langlais BT, Mazza GL, Thanarajasingam G, Deal AM, et al. Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences. Cancers. 2026;18(14):2265. doi:10.3390/cancers18142265
BibTeX
@article{Lee2026,
author = {Lee, Minji K and Dueck, Amylou C and Langlais, Blake T and Mazza, Gina L and Thanarajasingam, Gita and Deal, Allison M and Noble, Brie N and Rogak, Lauren and Mendoza, Tito R and Mitchell, Sandra A and Basch, Ethan},
title = {Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2265},
doi = {10.3390/cancers18142265}
}
EUVIMED